Lumos Pharma, INC
Market Movers (8-K)
Lumos Pharma has completed its merger with DPV Merger Sub, resulting in the company becoming a wholly-owned subsidiary of DPV Parent, Inc. and ceasing to be listed on the Nasdaq.
Lumos Pharma received a delisting notice from Nasdaq due to insufficient stockholders' equity, while also announcing positive Phase 2 clinical trial results for its drug LUM-201.
Better than expected
Insider Trading (Form 4)
Lumos Pharma's CEO, Richard J. Hawkins, disposed of shares and stock options as part of a merger agreement with Double Point Ventures LLC.
A Lumos Pharma executive, Zoth Lota S., exercised and disposed of various stock options following the company's merger with DPV Parent, Inc.
Lumos Pharma's Chief Scientific Officer, John C. McKew, exercised and disposed of various stock options and common stock holdings as part of a merger agreement with DPV Parent, Inc.
A Lumos Pharma executive, Chad Allen Johnson, exercised stock options and disposed of shares as part of a merger agreement with Double Point Ventures LLC.
A Lumos Pharma executive, An van Es-Johansson, has exercised and disposed of stock options as part of a merger agreement with Double Point Ventures LLC.
Lumos Pharma executive Raffin Thomas A. disposed of stock options as part of a merger agreement with Double Point Ventures LLC.